You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Bulk Pharmaceutical API Sources for ZICONOTIDE ACETATE


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for ZICONOTIDE ACETATE

Vendor Vendor Homepage Vendor Sku API Url
NovoSeek ⤷  Start Trial 16129690 ⤷  Start Trial
ISpharm ⤷  Start Trial I06-1841 ⤷  Start Trial
ChemMol ⤷  Start Trial 49401954 ⤷  Start Trial
AKos Consulting & Solutions ⤷  Start Trial AKOS015896032 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for Ziconotide Acetate

Last updated: February 20, 2026

Ziconotide acetate, marketed as Prialt, is a synthetic peptide derived from cone snail venom. Its manufacturing involves complex processes requiring high purity standards. Key API sourcing options include established contract manufacturers, specialized peptide producers, and chemical intermediates suppliers globally.

Primary API Manufacturers and Suppliers

Contract Manufacturing Organizations (CMOs)

Company Location Capacity Notable Capabilities Notes
Polypeptide Group UK High-volume Peptide synthesis, purification Supplies clinical and commercial quantities
Bachem Switzerland, USA Varied Peptide manufacturing, GMP facilities Produces ziconotide under licensing agreements
WuXi AppTec China Large-scale Peptide synthesis, analytical testing Offers integrated development-to-commercial services
Novasep France Medium Peptide synthesis, purification Specializes in complex peptides

Peptide Specialty Manufacturers

Company Location Focus Unique Abilities Notes
GenScript US Custom peptide synthesis High purity, rapid turnaround Provides scaled batches for clinical trials
Peptide Interactive UK Custom peptides Focus on difficult sequences Capable of GMP-grade API production

Chemical Intermediate Suppliers

Some suppliers provide the raw materials or intermediates used in peptide synthesis. These include amino acids or peptide building blocks.

Company Location Product Certification Notes
Merck KGaA Germany Amino acids GMP-compliant Supplies for peptide synthesis
Cayman Chemical USA Peptide reagents Research-grade Used in production scaling

Geographic Distribution of API Sources

  • Europe: Polypeptide Group, Bachem, Novasep
  • North America: WuXi AppTec, GenScript
  • Asia: WuXi AppTec, Peptide Interactive, large-scale Chinese peptide producers

Regulatory and Quality Considerations

API suppliers must comply with Good Manufacturing Practice (GMP) standards. Suppliers with approved GMP facilities can supply APIs for commercial use in regulated markets (US FDA, EMA). Procurement involves validation of supplier quality systems, batch release documentation, and traceability.

Sourcing Challenges and Risks

  • Complex synthesis: Peptide APIs like ziconotide acetate require advanced synthesis techniques and rigorous purification, which limits the number of capable suppliers.
  • Regulatory approval: Some suppliers may not hold GMP certifications, restricting their use for commercial manufacturing.
  • Supply chain stability: Dependence on a limited number of providers increases vulnerability, particularly during geopolitical or manufacturing disruptions.

Conclusion

Reliable APIs for ziconotide acetate predominantly come from specialized peptide manufacturers with GMP certification. Established CMOs such as Polypeptide, Bachem, WuXi, and Novasep lead global supply options. Access and continuity depend on supplier validation, regulatory compliance, and manufacturing capacity.

Key Takeaways

  • Ziconotide acetate APIs are produced mainly by peptide-focused CMOs with GMP compliance.
  • Major sources include Polypeptide Group, Bachem, WuXi AppTec, and Novasep.
  • Geographic distribution spans Europe, North America, and Asia, with supply chain risks based on supplier capacity and regulation status.
  • Validation involves rigorous quality control, documentation, and regulatory approval procedures.
  • Supply chain risks necessitate diversification and supplier qualification.

FAQs

1. What are the main challenges in sourcing ziconotide acetate APIs?
Manufacturing complexity, need for GMP compliance, and limited specialized producers create barriers. Certification and supply capacity are critical.

2. Can smaller biotech companies access GMP-grade ziconotide APIs?
Yes. Larger providers like GenScript and Peptide Interactive offer GMP materials suitable for clinical use; however, capacity for commercial scale must be verified.

3. What are the typical lead times for API procurement?
Lead times vary from 8 to 20 weeks depending on supplier, order size, and regulatory clearance processes.

4. Are there regional restrictions on API sourcing?
Regulatory agencies require GMP certification and batch documentation. Some regions restrict API importation without proper validation.

5. How does supplier qualification impact production?
Qualifying suppliers ensure API quality, regulatory compliance, and supply stability, reducing risks in commercial manufacturing.


References

[1] U.S. Food and Drug Administration. (2022). Good Manufacturing Practices for Drugs.
[2] European Medicines Agency. (2022). Guidelines on Good Manufacturing Practice.
[3] Polypeptide Group. (2023). API manufacturing capabilities.
[4] Bachem. (2023). Peptide production services.
[5] WuXi AppTec. (2023). Integrated peptide manufacturing solutions.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.